Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropyl- cyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion

Comparison with voglibose and glibenclamide

Takao Ikenoue, Kyoko Okazaki, Shoji Fujitani, Yoshiharu Tsuchiya, Megumi Akiyoshi, Toshio Maki, Nobuo Kondo

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

(-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166) is a new nonsulfonylurea hypoglycemic agent that lowers blood glucose by stimulating insulin release. In the present study, we examined the effects of A-4166, voglibose (an α-glucosidase inhibitor), and glibenclamide (a sulfonylurea) on the postprandial glycemic increase in rats with or without diabetes mellitus. Oral administration of A-4166 (25-100 mg/kg) dose- dependently decreased blood glucose with a rapid onset and short duration in normal rats. On the other hand, glibenclamide (1-4 mg/kg) showed a slower onset of its hypoglycemic action, and voglibose (0.2 mg/kg) had no effect. In the case of postprandial glucose excursion, the carbohydrate-induced increase in blood glucose was reduced by oral administration of either A-4166 or voglibose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats. However, the efficacy of voglibose varied with the type of carbohydrate load. Glibenclamide produced a prolonged decrease in blood glucose without any appreciable effect on the initial glucose excursion. After sucrose loading, plasma insulin levels during the initial I h were significantly higher in A-4166-treated rats than in control rats, while voglibose completely inhibited the insulin response to sucrose. In glibenclamide-treated rats, an augmented insulin response was not seen. In conclusion, unlike other hypoglycemic agents, A-4166 suppresses postprandial glucose excursions by stimulating the early phase of insulin secretion.

Original languageEnglish
Pages (from-to)354-359
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume20
Issue number4
Publication statusPublished - 1997 Apr
Externally publishedYes

Fingerprint

nateglinide
Glyburide
Phenylalanine
Hypoglycemic Agents
Blood Glucose
Insulin
Glucose
Oral Administration
Sucrose
Carbohydrates
Glucosidases
Streptozocin
Hypoglycemia
voglibose
Diabetes Mellitus

Keywords

  • A-4166
  • glibenclamide
  • insulin secretion
  • postprandial blood glucose excursion
  • voglibose

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropyl- cyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion : Comparison with voglibose and glibenclamide. / Ikenoue, Takao; Okazaki, Kyoko; Fujitani, Shoji; Tsuchiya, Yoshiharu; Akiyoshi, Megumi; Maki, Toshio; Kondo, Nobuo.

In: Biological and Pharmaceutical Bulletin, Vol. 20, No. 4, 04.1997, p. 354-359.

Research output: Contribution to journalArticle

Ikenoue, Takao ; Okazaki, Kyoko ; Fujitani, Shoji ; Tsuchiya, Yoshiharu ; Akiyoshi, Megumi ; Maki, Toshio ; Kondo, Nobuo. / Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropyl- cyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion : Comparison with voglibose and glibenclamide. In: Biological and Pharmaceutical Bulletin. 1997 ; Vol. 20, No. 4. pp. 354-359.
@article{28716d9f517e4208a9f33e35b2b093fb,
title = "Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropyl- cyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion: Comparison with voglibose and glibenclamide",
abstract = "(-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166) is a new nonsulfonylurea hypoglycemic agent that lowers blood glucose by stimulating insulin release. In the present study, we examined the effects of A-4166, voglibose (an α-glucosidase inhibitor), and glibenclamide (a sulfonylurea) on the postprandial glycemic increase in rats with or without diabetes mellitus. Oral administration of A-4166 (25-100 mg/kg) dose- dependently decreased blood glucose with a rapid onset and short duration in normal rats. On the other hand, glibenclamide (1-4 mg/kg) showed a slower onset of its hypoglycemic action, and voglibose (0.2 mg/kg) had no effect. In the case of postprandial glucose excursion, the carbohydrate-induced increase in blood glucose was reduced by oral administration of either A-4166 or voglibose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats. However, the efficacy of voglibose varied with the type of carbohydrate load. Glibenclamide produced a prolonged decrease in blood glucose without any appreciable effect on the initial glucose excursion. After sucrose loading, plasma insulin levels during the initial I h were significantly higher in A-4166-treated rats than in control rats, while voglibose completely inhibited the insulin response to sucrose. In glibenclamide-treated rats, an augmented insulin response was not seen. In conclusion, unlike other hypoglycemic agents, A-4166 suppresses postprandial glucose excursions by stimulating the early phase of insulin secretion.",
keywords = "A-4166, glibenclamide, insulin secretion, postprandial blood glucose excursion, voglibose",
author = "Takao Ikenoue and Kyoko Okazaki and Shoji Fujitani and Yoshiharu Tsuchiya and Megumi Akiyoshi and Toshio Maki and Nobuo Kondo",
year = "1997",
month = "4",
language = "English",
volume = "20",
pages = "354--359",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "4",

}

TY - JOUR

T1 - Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4-isopropyl- cyclohexanecarbonyl)-D-phenylalanine], on postprandial blood glucose excursion

T2 - Comparison with voglibose and glibenclamide

AU - Ikenoue, Takao

AU - Okazaki, Kyoko

AU - Fujitani, Shoji

AU - Tsuchiya, Yoshiharu

AU - Akiyoshi, Megumi

AU - Maki, Toshio

AU - Kondo, Nobuo

PY - 1997/4

Y1 - 1997/4

N2 - (-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166) is a new nonsulfonylurea hypoglycemic agent that lowers blood glucose by stimulating insulin release. In the present study, we examined the effects of A-4166, voglibose (an α-glucosidase inhibitor), and glibenclamide (a sulfonylurea) on the postprandial glycemic increase in rats with or without diabetes mellitus. Oral administration of A-4166 (25-100 mg/kg) dose- dependently decreased blood glucose with a rapid onset and short duration in normal rats. On the other hand, glibenclamide (1-4 mg/kg) showed a slower onset of its hypoglycemic action, and voglibose (0.2 mg/kg) had no effect. In the case of postprandial glucose excursion, the carbohydrate-induced increase in blood glucose was reduced by oral administration of either A-4166 or voglibose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats. However, the efficacy of voglibose varied with the type of carbohydrate load. Glibenclamide produced a prolonged decrease in blood glucose without any appreciable effect on the initial glucose excursion. After sucrose loading, plasma insulin levels during the initial I h were significantly higher in A-4166-treated rats than in control rats, while voglibose completely inhibited the insulin response to sucrose. In glibenclamide-treated rats, an augmented insulin response was not seen. In conclusion, unlike other hypoglycemic agents, A-4166 suppresses postprandial glucose excursions by stimulating the early phase of insulin secretion.

AB - (-)-N-(trans-4-Isopropylcyclohexanecarbonyl)-D-phenylalanine (A-4166) is a new nonsulfonylurea hypoglycemic agent that lowers blood glucose by stimulating insulin release. In the present study, we examined the effects of A-4166, voglibose (an α-glucosidase inhibitor), and glibenclamide (a sulfonylurea) on the postprandial glycemic increase in rats with or without diabetes mellitus. Oral administration of A-4166 (25-100 mg/kg) dose- dependently decreased blood glucose with a rapid onset and short duration in normal rats. On the other hand, glibenclamide (1-4 mg/kg) showed a slower onset of its hypoglycemic action, and voglibose (0.2 mg/kg) had no effect. In the case of postprandial glucose excursion, the carbohydrate-induced increase in blood glucose was reduced by oral administration of either A-4166 or voglibose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats. However, the efficacy of voglibose varied with the type of carbohydrate load. Glibenclamide produced a prolonged decrease in blood glucose without any appreciable effect on the initial glucose excursion. After sucrose loading, plasma insulin levels during the initial I h were significantly higher in A-4166-treated rats than in control rats, while voglibose completely inhibited the insulin response to sucrose. In glibenclamide-treated rats, an augmented insulin response was not seen. In conclusion, unlike other hypoglycemic agents, A-4166 suppresses postprandial glucose excursions by stimulating the early phase of insulin secretion.

KW - A-4166

KW - glibenclamide

KW - insulin secretion

KW - postprandial blood glucose excursion

KW - voglibose

UR - http://www.scopus.com/inward/record.url?scp=0030971593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030971593&partnerID=8YFLogxK

M3 - Article

VL - 20

SP - 354

EP - 359

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 4

ER -